Novartis AG $NVS Shares Sold by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC lessened its holdings in Novartis AG (NYSE:NVS) by 9.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,971 shares of the company’s stock after selling 3,980 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Novartis were worth $6,107,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in NVS. J.W. Cole Advisors Inc. boosted its stake in shares of Novartis by 0.6% during the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after acquiring an additional 64 shares in the last quarter. Roundview Capital LLC grew its position in shares of Novartis by 2.5% in the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after purchasing an additional 66 shares during the period. CPC Advisors LLC increased its stake in shares of Novartis by 4.6% during the 2nd quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock valued at $238,000 after acquiring an additional 66 shares during the last quarter. IMA Advisory Services Inc. increased its position in Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after purchasing an additional 70 shares during the last quarter. Finally, Moody National Bank Trust Division increased its holdings in shares of Novartis by 4.2% during the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock worth $282,000 after buying an additional 72 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

More Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: The stock showed signs of rebounding after its steep selloff, suggesting some investors may view the decline as an overreaction and remain confident in Novartis’s established medicines portfolio. Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
• Neutral Sentiment: Investors are focusing on how Novartis deployed roughly $30 billion in recent deals, as several acquired programs have encountered clinical setbacks. The scrutiny could lead to changes in capital-allocation priorities, deal approval processes or board composition. Focus: Novartis investors turn spotlight on M&A after trial setbacks
• Negative Sentiment: Experimental drug del-desiran failed to produce a statistically significant improvement in a late-stage trial for myotonic dystrophy type 1. The failure removes a potentially important growth asset and adds to concerns about Novartis’s pipeline. Drug Trial Setbacks Raise Questions Over Novartis’s Growth Pipeline
• Negative Sentiment: Del-desiran was the second major trial setback in a short period, contributing to a sharp weekly selloff and making investors question whether acquisitions are generating sufficient pipeline value. Deutsche Bank responded by cutting its view on the stock. Novartis extends selloff as Deutsche Bank cuts on twin drug trial setbacks
• Negative Sentiment: A major shareholder has called for a board shake-up, arguing that stronger oversight is needed after the trial failures and share-price decline. The challenge adds reputational and execution risk for management. Major Novartis shareholder calls for board shake-up after drug trial setbacks

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Royal Bank Of Canada started coverage on shares of Novartis in a report on Tuesday. They issued a “sector perform” rating on the stock. Deutsche Bank Aktiengesellschaft downgraded Novartis from a “buy” rating to a “hold” rating in a report on Tuesday. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. HSBC set a $136.00 target price on Novartis in a research report on Thursday. Finally, Citigroup reaffirmed a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $153.00.

Novartis Stock Down 0.2%

NVS stock opened at $137.22 on Friday. The company has a market capitalization of $261.84 billion, a price-to-earnings ratio of 20.70, a price-to-earnings-growth ratio of 2.67 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. Novartis AG has a 52 week low of $121.57 and a 52 week high of $170.46. The firm’s 50-day moving average is $154.18 and its two-hundred day moving average is $153.00.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The company had revenue of $14.95 billion for the quarter. On average, analysts forecast that Novartis AG will post 8.84 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.